Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MVG is an oral multivitamin and mineral complex formulation developed to alleviate symptoms and stabilize tear film in patients with intractable dry eye. It contains tocopherol acetate, ascorbic acid, thiamine nitrate, riboflavin, pyridoxine HCl, β-carotene, zinc oxide, selenium, and ubidecarenone. The drug works primarily through its antioxidant and anti-inflammatory properties, addressing oxidative stress and inflammation which are key mechanisms in dry eye disease. It also contributes to neuropathic pain alleviation, ocular surface protection, and promotion of goblet cell proliferation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MVG.